Actively Recruiting
Phase 1b Study of Pasritamig IV and Oral JNJ-86974680 Combination for Advanced Prostate Cancer Treatment
Led by Janssen Research & Development, LLC · Updated on 2026-07-06
40
Participants Needed
5
Research Sites
16 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying the combination of Pasritamig and JNJ-86974680 to find the recommended phase 2 dose and to evaluate its safety and tolerability in treating advanced prostate cancer. The study focuses on participants with metastatic castration-resistant prostate cancer, aiming to understand how these drugs work together in this population. The study has two parts. In Part 1, participants receive Pasritamig intravenously combined with oral JNJ-86974680 to determine the best dose for further study. In Part 2, participants receive this recommended dose to confirm its safety and assess its anti-tumor effects. Both drugs are given as part of a treatment regimen designed to target prostate cancer cells. Participants will be monitored for up to about 14 months, including assessments of adverse events, dose-limiting toxicities, tumor response, prostate-specific antigen levels, and disease progression. Researchers will collect blood samples to measure drug levels and antibodies. Safety and treatment effects will be closely followed throughout the study period to understand how participants respond to the combination therapy.
CONDITIONS
Brief Title
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
Research Team
S
Study Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
